


## **B-Cell Development and Activation**










### Immunofixation Electrophoresis (IFE)



λ

#### RESEARCH ARTICLE

# Gamma gap thresholds and HIV, hepatitis C, and monoclonal gammopathy

Gigi Y. Liuo<sup>1e</sup>\*, Olive Tang<sup>2e</sup>, Daniel J. Brotman<sup>1</sup>, Edgar R. Miller, III<sup>1,2</sup>, Alison R. Moliterno<sup>3</sup>, Stephen P. Juraschek<sup>1,4</sup>

Table 2. Diagnostic performance of gamma gap for HIV using different gamma gap thresholds, N = 25,6	Table 2.	. Diagnostic r	performance of	gamma gap	for HIV	using different	gamma	gap thresho	lds, N = 25,6	580.
---	----------	----------------	----------------	-----------	---------	-----------------	-------	-------------	---------------	------

Gamma gap (g/dL)	Sn, %	Sp, %	LR +	LR -	Overall AUC (95% CI)
≥ 2.5	94.8	10.5	1.1	0.5	0.80 (95% CI: 0.75, 0.85)
≥ 3.0	84.4	51.9	1.8	0.3	
≥ 3.5	59.3	88.1	5.0	0.5	
$\geq 4.0$	39.3	98.4	24.2	0.6	
≥ 4.5	19.3	99.6	54.1	0.8	
≥ 5.0	10.4	99.9	139.4	0.9	
≥ 5.5	4.4	100.0	283.9	1.0	

Table 3. Diagnostic performance of gamma gap for HCV using different gamma gap threshold, N = 45,134.

Gamma gap (g/dL)	Sn, %	Sp, %	LR +	LR -	Overall AUC (95% CI)
≥ 2.5	97.8	9.9	1.1	0.2	0.74 (95% CI: 0.72, 0.76)
≥ 3.0	80.8	50.2	1.6	0.4	
≥ 3.5	44.5	86.9	3.4	0.6	
$\geq 4.0$	19.0	97.8	8.5	0.8	
≥ 4.5	7.0	99.5	13.7	0.9	
≥ 5.0	2.6	99.8	16.3	1.0	
≥ 5.5	1.1	99.9	13.9	1.0	

Table 4. Diagnostic performance of gamma gap for MGUS using different gamma gap thresholds, N = 6,118.

Gamma gap (g/dL)	Sn, %	Sp, %	LR +	LR -	Overall AUC (95% CI)		
≥ 2.5	97.6	6.4	1.0	0.4	0.64 (95% CI: 0.60, 0.69)		
≥ 3.0	75.7	39.9	1.3	0.6			
≥ 3.5	39.1	80.1	2.0	0.8			
$\geq 4.0$	15.4	95.4	3.4	0.9			
≥ 4.5	7.7	98.9	6.9	0.9			
≥ 5.0	5.3	99.7	16.7	0.9			
≥ 5.5	3.0	99.8	17.6	1.0			

### Conclusions:

- Gamma gap is not a sufficient screening tool (you'd want high sensitivity for a screen)
- An elevated gamma gap warrants further testing for HCV and HIV but not MGUS
- Many patients with HIV and HCV did not have an elevated gamma gap
- HIV and HCV stage of treatment influence the gamma gap

### Limitations:

- This study was performed in defined patient populations, so patients with comorbid conditions were not assessed and there was no assessment of a mixed population (HIV, HCV, and MGUS)
- These were outpatients and none had autoimmune conditions, chronic inflammatory conditions, or chronic infections
- When the gamma gap was test further in this study
  - HIV: age > 18
  - HCV: age > 6
  - MGUS: age > 50

Original Article | Published: 30 July 2008

# A Clinical Decision Rule to Aid Ordering of Serum and Urine Protein Electrophoresis for Case-Finding of Paraproteins in Hospitalized Inpatients

Ammarin Thakkinstian PhD, Huy Tran MB BS, FRACP, Glenn Reeves MB BS, FRACP, Stuart Murch B Med & John Attia PhD, FRCPC, FRACP

Journal of General Internal Medicine 23, 1688–1692 (2008) Cite this article

For MGUS use the following equation:

$$Logit\left[\frac{SPE/UPE^{+}}{SPE/UPE^{-}}\right] = -4.4 + 1.5 x globulin + 1.1 x age + 0.6 x hgb + 0.4 x sex + .2 x gfr$$

Variables	OR (95% CI)	Scores	
Globulin, g/l			
>41	4.5 (3.8, 5.4)	5	
≤41		0	
Age, years			
≥60	2.9 (2.4, 3.7)	3	1.00 -
<60		0	0.90 -
Hemoglobin	, g/1		- 08.0
<121	1.9 (1.5, 2.3)	2	0.70 -
≥121		0	0.60 -
Sex			Sensitivity 0.50 -
Male	1.6 (1.4, 1.9)	2	0.40 -
Female		0	0.30 -
eGFR, m1/m	in/1.73 m <sup>2</sup>		0.20 -
<60	1.3 (1.1, 1.5)	1	0.10 -
≥60		0	0.00 -
Total scores		0-13	0.

Score (prob. of para-protein)	Derivation set				Validation set			
	SPE/UPE		LR <sup>+</sup> (95% CI)	PPV (%)	SPE/UPE		LR <sup>+</sup> (95% CI)	PPV(%)
	Positive	Negative			Positive	Negative		
0-5(Low)	207	6,537	1.0	3.1	91	2,797	1.0	3.1
6-10(Med)	303	2,205	2.5(2.4-2.7)	12.1	129	941	2.5(2.3-2.7)	12.1
≥11(High)	294	506	6.7(5.9–7.6)	36.8	127	221	6.6(5.4-79)	36.5